Table 2.
Demographic information for patients who provided fibroblasts
| Patient | Age/Sex | Histology | KL-6a (U/mL) | SP-Db (ng/mL) | FVC (L) | FEV1.0 (L) | TLC (L) | DLco (mL/min/mmHg) | |
|---|---|---|---|---|---|---|---|---|---|
| With ILD | 1 | 84/M | Sq | 613 | 159 | 2.13 | 1.76 | 3.84 | 6.06 |
| 2 | 69/M | Sq | 622 | 159 | 3.07 | 2.23 | 4.29 | 8.79 | |
| 3 | 64/M | Ad | 1129 | 321 | 2.77 | 2.27 | 4.25 | 12.0 | |
| 4 | 79/M | Sq | 599 | 62.4 | 2.85 | 2.14 | 4.36 | 9.75 | |
| 5 | 77 M | Sq | 658 | 103 | 2.71 | 2.21 | 4.32 | 12.9 | |
| Without ILD | 1 | 81/F | Ad | NDc | NDc | 1.95 | 1.45 | 3.24 | 9.84 |
| 2 | 79/F | Sq | NDc | NDc | 2.27 | 1.76 | 3.98 | 12.8 | |
| 3 | 81/M | Ad | NDc | NDc | 3.17 | 2.18 | 5.39 | 16.3 |
Definition of abbreviations:
ILD interstitial lung disease, Sq squamous cell carcinoma, Ad adenocarcinoma, SP-D surfactant protein-D, FVC forced vital capacity, FEV1.0 forced expiratory volume 1.0 (sec), TLC total lung capacity, Dlco diffusing capacity of the lung carbon monoxide
aNormal range of serum KL-6 is <500U/mL
bNormal range of serum SP-D is <110 ng/mL
cThe serum levels of KL-6 and SP-D in the patients without ILD were not examined